Skip to content
Study details
Enrolling now

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

NYU Langone Health
NCT IDNCT05799378ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

330

Study length

about 5 years

Ages

60+

Locations

10 sites in CA, NJ, NY +2

What this study is about

This trial is testing whether it's safe to stop hydroxychloroquine (HCQ) medication for elderly people with lupus. The goal is to see if HCQ can be safely stopped in stable patients, and how their disease activity changes when they no longer take the drug.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Hydroxychloroquine
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

hydroxychloroquine (Antimalarial; increases pH in parasite)

Drug routes

oral

Endpoints

Secondary: Change in 29-Question Patient-Reported Outcomes Measurement Information System (PROMIS-29) Score, Change in 36-Item Short Form Survey Instrument (SF-36) Score, Number of Participants with New Retinal Toxicity

Body systems

Immune